Kübra Kilic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kübra Kilic has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Henrik Bjarke Vaegter
Pain Research Group, Pain Center, Department of Anaesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark
3 shared publications - Jonas Bloch Thorlund
Center for Muscle and Joint Health, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark
3 shared publications - Preben Kidmose
Department of Electrical and Computer Engineering Aarhus University Aarhus Denmark
3 shared publications - Bart Willem Koes
Erasmus Medical center, Department of General Practice, Rotterdam, The Netherlands; Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark
2 shared publications - Jan Hartvigsen
Center for Muscle and Joint Health, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark
2 shared publications - Jens Søndergaard
University of Southern Denmark
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Journal of Sleep Research
Temporal Associations Between Physiological Sleep and Next‐Day Pain Intensity in Individuals With Activity‐Limiting Chronic Pain: A Multiple Night At‐Home Ear‐ EEG Sleep‐Monitoring Study
Chronic pain and sleep disturbances frequently co‐occur. However, most prior research relies on self‐report or actigraphy, which reflect behavioural aspects of sleep but provide only limited insight into the underlying sleep physiology. In this pre‐registered prospective observational study (NCT06368531), we investigated within‐person night‐to‐night variability in physiological sleep metrics and explored temporal associations between sleep metrics and next‐day pain. Individuals with bothersome ( n = 4) or high‐impact ( n = 15) chronic pain completed between 11 and 33 nights of at‐home sleep monitoring using an ear‐EEG device and rated morning pain intensity daily on a 0–10 numerical rating scale. This design enables assessment of real‐world physiological sleep patterns alongside natural fluctuations in pain, offering a high‐resolution view of sleep–pain dynamics beyond traditional diary or actigraphy‐based methods. Substantial between‐night variability was observed across multiple sleep metrics, such as sleep efficiency and sleep stage transitions (ICC values < 0.5), indicating that less than half of the total variance was attributable to differences between subjects, underscoring the importance of longitudinal within‐person monitoring. Mixed‐effects model analyses revealed that lower next‐day pain intensity was associated with greater duration ( β = −0.01, p = 0.005), higher percentage ( β = −0.07, p = 0.001) and increased stability ( β = −0.01, p = 0.013) of N3 sleep. In contrast, higher next‐day pain was associated with increased N3 fragmentation ( β = 0.01, p = 0.014) and a higher proportion of N1 sleep ( β = 0.014, p = 0.007). Together, these findings provide objective physiological support for previously reported associations between sleep and pain, highlighting the value of longitudinal ear‐EEG monitoring for capturing nightly sleep–pain dynamics. Trial Registration: ClinicalTrials.gov identifier: NCT06368531.
- 5 November 2026
- Published by Wiley in Journal of Sleep Research
Open AccessTemporal Associations Between Physiological Sleep and Next‐Day Pain Intensity in Individuals With Activity‐Limiting Chronic Pain: A Multiple Night At‐Home Ear‐ EEG Sleep‐Monitoring Study
Chronic pain and sleep disturbances frequently co‐occur. However, most prior research relies on self‐report or actigraphy, which reflect behavioural aspects of sleep but provide only limited insight into the underlying sleep physiology. In this pre‐registered prospective observational study (NCT06368531), we investigated within‐person night‐to‐night variability in physiological sleep metrics and explored temporal associations between sleep metrics and next‐day pain. Individuals with bothersome ( n = 4) or high‐impact ( n = 15) chronic pain completed between 11 and 33 nights of at‐home sleep monitoring using an ear‐EEG device and rated morning pain intensity daily on a 0–10 numerical rating scale. This design enables assessment of real‐world physiological sleep patterns alongside natural fluctuations in pain, offering a high‐resolution view of sleep–pain dynamics beyond traditional diary or actigraphy‐based methods. Substantial between‐night variability was observed across multiple sleep metrics, such as sleep efficiency and sleep stage transitions (ICC values < 0.5), indicating that less than half of the total variance was attributable to differences between subjects, underscoring the importance of longitudinal within‐person monitoring. Mixed‐effects model analyses revealed that lower next‐day pain intensity was associated with greater duration ( β = −0.01, p = 0.005), higher percentage ( β = −0.07, p = 0.001) and increased stability ( β = −0.01, p = 0.013) of N3 sleep. In contrast, higher next‐day pain was associated with increased N3 fragmentation ( β = 0.01, p = 0.014) and a higher proportion of N1 sleep ( β = 0.014, p = 0.007). Together, these findings provide objective physiological support for previously reported associations between sleep and pain, highlighting the value of longitudinal ear‐EEG monitoring for capturing nightly sleep–pain dynamics. Trial Registration: ClinicalTrials.gov identifier: NCT06368531.
- Open Access
- 17 November 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 513
Melatonin for chronic back pain (the MOCHA trial): study protocol for a randomized, double-blind, placebo-controlled trial
Background: Chronic back pain remains a leading cause of disability worldwide, with high societal and healthcare costs and limited effective treatment options. More than 50% of people with chronic back pain also report insomnia symptoms. Melatonin, primarily known for its use in treating insomnia and jetlag, has shown promising effects as a pain medication in chronic non-musculoskeletal pain conditions. We aim to determine the efficacy of 6 weeks of melatonin compared with placebo in reducing average pain intensity in patients with chronic disabling back pain. Method: The Melatonin for Chronic Back Pain (MOCHA) trial is a 1:1 randomized, placebo-controlled, double-blind, superiority trial including 220 patients with chronic disabling back pain randomized to either 10 mg (given as two 5 mg tablets) melatonin daily for 6 weeks or an identically looking placebo tablet. The primary outcome is the between-group difference in change in average pain intensity during the last 7 days from baseline to 6 weeks. Secondary outcomes include insomnia severity, back pain-related disability, global perceived effect, physical and mental health, and pain sensitivity. Exploratory outcomes are physiological sleep metrics assessed with ear electroencephalography (EEG). Discussion: This trial evaluates the efficacy of melatonin, an inexpensive and widely available intervention that could potentially reduce pain and sleep problems in a population with few effective treatment options available. Trial registration CTIS EU-CT 2023-503530-41-00. Registered on March 4th, 2024. ClinicalTrials.gov NCT06476392. Registered on June 20th, 2024.
- 17 November 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 513
Open AccessMelatonin for chronic back pain (the MOCHA trial): study protocol for a randomized, double-blind, placebo-controlled trial
Background: Chronic back pain remains a leading cause of disability worldwide, with high societal and healthcare costs and limited effective treatment options. More than 50% of people with chronic back pain also report insomnia symptoms. Melatonin, primarily known for its use in treating insomnia and jetlag, has shown promising effects as a pain medication in chronic non-musculoskeletal pain conditions. We aim to determine the efficacy of 6 weeks of melatonin compared with placebo in reducing average pain intensity in patients with chronic disabling back pain. Method: The Melatonin for Chronic Back Pain (MOCHA) trial is a 1:1 randomized, placebo-controlled, double-blind, superiority trial including 220 patients with chronic disabling back pain randomized to either 10 mg (given as two 5 mg tablets) melatonin daily for 6 weeks or an identically looking placebo tablet. The primary outcome is the between-group difference in change in average pain intensity during the last 7 days from baseline to 6 weeks. Secondary outcomes include insomnia severity, back pain-related disability, global perceived effect, physical and mental health, and pain sensitivity. Exploratory outcomes are physiological sleep metrics assessed with ear electroencephalography (EEG). Discussion: This trial evaluates the efficacy of melatonin, an inexpensive and widely available intervention that could potentially reduce pain and sleep problems in a population with few effective treatment options available. Trial registration CTIS EU-CT 2023-503530-41-00. Registered on March 4th, 2024. ClinicalTrials.gov NCT06476392. Registered on June 20th, 2024.
- Open Access
- 14 July 2025
- Published by Springer Nature in Research Square
Melatonin for Chronic Back Pain (The MOCHA trial): Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial
Background: Chronic back pain remains a leading cause of disablity worldwide with high societal and healthcare costs and limited effective treatment options. More than 50% of people with chronic back pain also report insomnia symptoms. Melatonin, primarily known for its use in treating insomnia and jetlag, has shown promising effects as a pain medication in chronic non-musculoskeletal pain conditions. We aim to determine the efficacy of 6 weeks of melatonin compared with placebo in reducing average pain intensity in patients with chronic disabling back pain. Method: The Melatonin for Chronic Back Pain (MOCHA) trial is a 1:1 randomized, placebo-controlled, double-blind, superiority trial including 220 patients with chronic disabling back pain randomized to either 10 mg melatonin daily for 6 weeks or an identically looking placebo tablet. The primary outcome is the between group difference in change in average pain intensity during the last 7 days from baseline to 6 weeks. Secondary outcomes include insomnia severity, back pain-related disability, global perceived effect, physical and mental health and pain sensitivity. Exploratory outcomes are physiological sleep metrics assessed with ear electroencephalography (EEG). Discussion: This trial evaluates the efficacy of melatonin, an inexpensive and widely available intervention that could potentially reduce pain and sleep problems in a population with few effective treatment options available. Trial registration: CTIS: EU-CT 2023-503530-41-00 (Registered on March 4 th 2024) ClinicalTrials.gov: NCT06476392 (Registered on June 20 th 2024)
- 14 July 2025
- Published by Springer Nature in Research Square
Open AccessMelatonin for Chronic Back Pain (The MOCHA trial): Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial
Background: Chronic back pain remains a leading cause of disablity worldwide with high societal and healthcare costs and limited effective treatment options. More than 50% of people with chronic back pain also report insomnia symptoms. Melatonin, primarily known for its use in treating insomnia and jetlag, has shown promising effects as a pain medication in chronic non-musculoskeletal pain conditions. We aim to determine the efficacy of 6 weeks of melatonin compared with placebo in reducing average pain intensity in patients with chronic disabling back pain. Method: The Melatonin for Chronic Back Pain (MOCHA) trial is a 1:1 randomized, placebo-controlled, double-blind, superiority trial including 220 patients with chronic disabling back pain randomized to either 10 mg melatonin daily for 6 weeks or an identically looking placebo tablet. The primary outcome is the between group difference in change in average pain intensity during the last 7 days from baseline to 6 weeks. Secondary outcomes include insomnia severity, back pain-related disability, global perceived effect, physical and mental health and pain sensitivity. Exploratory outcomes are physiological sleep metrics assessed with ear electroencephalography (EEG). Discussion: This trial evaluates the efficacy of melatonin, an inexpensive and widely available intervention that could potentially reduce pain and sleep problems in a population with few effective treatment options available. Trial registration: CTIS: EU-CT 2023-503530-41-00 (Registered on March 4 th 2024) ClinicalTrials.gov: NCT06476392 (Registered on June 20 th 2024)